Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants
Author(s)
Bajoria, Sakshi; Kaur, Kawaljit; Kumru, Ozan S; Van Slyke, Greta; Doering, Jennifer; Novak, Hayley; Rodriguez Aponte, Sergio A; Dalvie, Neil C; Naranjo, Christopher A; Johnston, Ryan S; Silverman, Judith Maxwell; Kleanthous, Harry; Love, J Christopher; Mantis, Nicholas J; Joshi, Sangeeta B; Volkin, David B; ... Show more Show less
DownloadPublished version (9.624Mb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
Low-cost, refrigerator-stable COVID-19 vaccines will facilitate global access and improve vaccine coverage
in low- and middle-income countries. To this end, subunit-based approaches targeting the receptorbinding domain (RBD) of SARS-CoV-2 Spike protein remain attractive. Antibodies against RBD neutralize
SARS-CoV-2 by blocking viral attachment to the host cell receptor, ACE2. Here, a yeast-produced recombinant RBD antigen (RBD-L452K-F490W or RBD-J) was formulated with various combinations of aluminum-salt (Alhydrogel®, AH; AdjuPhos®, AP) and CpG 1018 adjuvants. We assessed the effect of antigenadjuvant interactions on the stability and mouse immunogenicity of various RBD-J preparations. While
RBD-J was 50% adsorbed to AH and <15% to AP, addition of CpG resulted in complete AH binding, yet no
improvement in AP adsorption. ACE2 competition ELISA analyses of formulated RBD-J stored at varying
temperatures (4, 25, 37°C) revealed that RBD-J was destabilized by AH, an effect exacerbated by CpG. DSC
studies demonstrated that aluminum-salt and CpG adjuvants decrease the conformational stability of
RBD-J and suggest a direct CpG-RBD-J interaction. Although AH+CpG-adjuvanted RBD-J was the least
stable in vitro, the formulation was most potent at eliciting SARS-CoV-2 pseudovirus neutralizing antibodies in mice. In contrast, RBD-J formulated with AP+CpG showed minimal antigen-adjuvant interactions, a better stability profile, but suboptimal immune responses. Interestingly, the loss of in vivo potency
associated with heat-stressed RBD-J formulated with AH+CpG after one dose was abrogated by a booster.
Our findings highlight the importance of elucidating the key interrelationships between antigen-adjuvant
interactions, storage stability, and in vivo performance to enable successful formulation development of
stable and efficacious subunit vaccines.
Date issued
2022-06-06Department
Massachusetts Institute of Technology. Department of Biological Engineering; Koch Institute for Integrative Cancer Research at MIT; Massachusetts Institute of Technology. Department of Chemical EngineeringJournal
Human Vaccines & Immunotherapeutics
Publisher
Informa UK Limited
Citation
Bajoria, S., Kaur, K., Kumru, O. S., Van Slyke, G., Doering, J., Novak, H., … Volkin, D. B. (2022). Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants. Human Vaccines & Immunotherapeutics, 18(5).
Version: Final published version